Our Story

Relievant Medsystems is a privately held medical device company with headquarters in Sunnyvale, California. Based on two decades of scientific research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic low back pain.

After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device industry’s first successful Level 1, randomized sham-controlled trial for chronic low back pain.

The Intracept System received 510(k) Clearance based, in part, upon the outcomes of the SMART Trial. More recently, Relievant received 510(k) Clearance for the second generation Access Instruments and Radiofrequency Generator.

Relievant is now sponsoring the INTRACEPT Study — a Level 1, prospective, randomized clinical study comparing the Intracept Procedure to conservative care for patients with chronic low back pain. The INTRACEPT Study was initiated in September 2017.

  • 2006

    October: Relievant is Founded

  • 2007

    April: Pilot Study Initiated

  • 2008

    September: CE Mark Approval

  • 2010

    June: Pilot Study Completed

  • 2011

    July: FDA Approves IDE SMART Trial

    September: First Patient Enrolled in SMART Trial

  • 2015

    February: SMART Trial Completed

  • 2016

    July: FDA 510(k) Clearance for the Intracept System

  • 2017

    August: FDA 510(k) Clearance for Second Generation Access Instruments and Radio frequency Generator

    September: INTRACEPT Study Initiated

1 Becker S, Hadjipavlou A, Heggeness M, Ablation of the basivertebral nerve for treatment of back pain: a clinical study. The Spine Journal: Official Journal of the North American Spine Society 2017; 17: 218–223